Nyrada (ASX:NYR) received human research ethics committee approval to modify its phase one clinical trial protocol, according to a Wednesday Australian bourse filing.
The amendments allow for the evaluation of the safety, tolerability, and pharmacokinetics of Xolatryp, a small-molecule cardioprotection and neuroprotection therapy candidate, in healthy volunteers at higher doses and over a longer infusion duration.
The phase one trial will consist of six cohorts, and results are expected in the September quarter.
The amended protocol will give the firm greater flexibility in designing a phase two trial, including the ability to optimize dosing for the target patient population, per the filing.
The firm's shares fell 3% in recent trading on Wednesday.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。